138 results on '"Giammarco, S."'
Search Results
2. Cord blood resilience in a patient with relapsing Ph + B lymphoblastic acute leukemia after hematopoietic stem cell transplantation
3. P1353: EFFICACY OF SARSCOV2 VACCINATION IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION. A MULTICENTER EXPERIENCE
4. “A pilot study on the efficacy of Lactobacillus brevis CD2 lozenges in preventing oral mucositis by high-dose chemotherapy with autologous hematopoietic stem cell transplantation”: AB55
5. P21 - Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: SIMILAR MOLECULAR PATTERN IN T-AML IN PATIENTS TREATED WITH PARP INHIBITORS FOR METASTATIC OVARIAN CANCER
6. Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations
7. The role of HLA–G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis
8. CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) AND THEIR IMPACT ON AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTOSCT): A SINGLE CENTER EXPERIENCE: PH-AB063
9. EPIDEMIOLOGY AND MANAGEMENT OF CARBAPENEMASE-PRODUCING KLEBSIELLA PNEUMONIA INFECTIONS IN ALLOGENIC HSCT RECIPIENTS: A SINGLE CENTER EXPERIENCE: PH-P485
10. Correlation between paraproteinaemia and viral reactivation after allo-SCT
11. Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia
12. FECAL calprotectin as non-invasive biomarker of acute and chronic GvHD in allogeneic stem cell transplantation: P489
13. Proteomic patterns and graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: O149
14. Use of eltrombopag in aplastic anemia in Europe
15. Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia
16. Absence of JAK-2V617F point mutations in multiple myeloma
17. Screening of JAK2 V617F mutation in multiple myeloma
18. PF780 STEM CELL TRANSPLANTATION FOR ACQUIRED APLASTIC ANEMIA: THE ROLE OF THE CONDITIONING REGIMEN
19. PF759 ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES FROM HLA IDENTICAL SIBLINGS OR HAPLOIDENTICAL DONORS: A COMPARISON
20. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey
21. Reply to ‘Absence of JAK-2 (Val617Phe) point mutations in multiple myeloma’ by Dr Qin Huang et al. referred to ‘Screening of JAK2 V617F mutation in multiple myeloma’ from Fiorini A et al. published in Leukemia 2006, October 20
22. The role of HLA–G 14bp polymorphism in allogeneic haematopoietic stem cell transplantation after short-term course methotrexate for graft-versus host disease prophylaxis
23. Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia
24. The role of HLA–G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis
25. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue.
26. SECOND TRANSPLANTATION FOR PRIMARY GRAFT FAILURE, FOLLOWING HAPLOIDENTICAL GRAFTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE
27. CARBAPENEM-RESISTANT ENTEROBACTERIACEAE AND THEIR IMPACT ON STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
28. Blinatumomab for the Treatment of Relapsed/refractory B-acute Lymphoblastic Leukemia: Report from a Single Center
29. Rate of re-admission in patients undergoing allogeneic transplants from identical siblings, unrelated donors or haploidentical donors
30. Comprehensive Geriatric Assessment, Allogeneic HSCT and Survival in AML Patients 65-75 Years Old
31. CD34 EXPRESSION CUT-OFF VALUE FOR PREDICTION OF PML-RAR alpha ISOFORMS IN ADULT ACUTE PROMYELOCYTIC LEUKEMIA
32. UNMANIPULATED HAPLOIDENTICAL MARROW TRANSPLANTATION WITH A MODIFIED POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) REGIMEN: AN UPDATE OF THE GENOVA-ROME GEMELLI EXPERIENCE
33. EFFICACY AND SAFETY PROFILE OF FOSCARNET AS PRE-EMPTIVE THERAPY FOR CYTOMEGALOVIRUS INFECTION IN HEMATOPOIETIC STEM CELL TRANSPANT RECIPIENTS
34. VITAMIN B12 DEFICIENCY: CORRELATION BETWEEN MTHFR POLYMORPHISMS AND CLINICAL AND LABORATORY FINDINGS
35. CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) AND THEIR IMPACT ON AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTOSCT): A SINGLE CENTER EXPERIENCE
36. EPIDEMIOLOGY AND MANAGEMENT OF CARBAPENEMASE-PRODUCING KLEBSIELLA PNEUMONIA INFECTIONS IN ALLOGENIC HSCT RECIPIENTS: A SINGLE CENTER EXPERIENCE
37. ACUTE GRAFT VERSUS HOST DISEASE: REDUCED INCIDENCE AND PREDICTIVE FACTORS
38. Triple PTCY Based GVHD Prophylaxis: HLA Matched Versus HLA Haploidentical Transplants
39. ROLE OF FLOW-CYTOMETRIC IMMUNOPHENOTYPING IN PREDICTION OF BCR/ABL GENE REARRANGEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
40. MTHFR polymorphisms and vitamin B12 deficiency: correlation between mthfr polymorphisms and clinical and laboratory findings.
41. Severe breakthrough hemolysis during compassionate use of Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: managing an emergency.
42. Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review.
43. CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation.
44. Post-transplant cyclophosphamide with Sirolimus or Cyclosporine for GvHD prophylaxis in matched related and unrelated transplantation: a two-center analysis on 213 consecutive patients.
45. Haploidentical bone marrow transplantation for AML in remission after TBF conditioning: a long-term follow-up.
46. Unselected donor-derived hematopoietic stem cells boost for Chimeric Antigen Receptor T-cell associated hematotoxicity.
47. Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir-exposed CMV-free population receiving PTCy.
48. Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T-cells (CAR-T): A comprehensive review on incidence, risk factors and current management.
49. Acute graft versus host disease 1976-2020: reduced incidence and predictive factors.
50. SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.